ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

This study (ARTEMIS-008) is comparing a new drug called HS-20093 to the standard chemotherapy drug topotecan in people with small cell lung cancer (SCLC) that has come back after initial treatment. **You may be eligible if...** - You are 18 or older with confirmed small cell lung cancer - Your cancer has progressed after at least one round of platinum-based chemotherapy - You have at least one measurable tumor on imaging - Your general health score (ECOG) is 0 or 1 and estimated survival is more than 12 weeks - You are not pregnant and are using contraception if applicable **You may NOT be eligible if...** - You have not previously received platinum-based chemotherapy for SCLC - You have active brain metastases that are untreated - You have serious heart conditions or are on medications that interact with the study drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.